FDA Grants Breakthrough Therapy Designation to Bezuclastinib Plus Sutent for Advanced GIST After GLEEVEC Failure
The Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to bezuclastinib in combination with Sutent (sunitinib) for adults with advanced gastrointestinal stromal tumors (GIST) whose disease has progressed on, or become resistant to, GLEEVEC (imatinib), according to a recent update